Загрузка...
Checkpoint inhibitors in the treatment of urological malignancies
Checkpoint inhibitors are monoclonal antibodies attach to several different receptors on T-cells or tumour cells expressing receptors for cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed death-1 (PD-1) and their ligand (PD-L1). Since 2010, numerous trials on different tumour types have been con...
Сохранить в:
| Опубликовано в: : | ESMO Open |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BMJ Publishing Group
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5519795/ https://ncbi.nlm.nih.gov/pubmed/28761743 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2017-000165 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|